MMP13 rs2252070: Promoter Variation and Tissue Remodeling
The genetic variant rs2252070 is a single-nucleotide polymorphism located within the promoter region of the matrix metallopeptidase gene family, frequently referenced in functional literature as MMP13 -77A>G (and historically examined alongside MMP promoter polymorphisms). Studies indicate that this nucleotide exchange alters transcription factor binding motifs, influencing promoter activity and baseline enzyme transcription in various tissues. Research into this variant focuses on its statistical associations with tissue remodeling, inflammatory responses, and epithelial tumor susceptibility, though overall clinical evidence remains preliminary.
What each genotype means
Baseline promoter activity
This genotype is associated with baseline transcriptional activity of the MMP13 gene. Research indicates that the A allele may exhibit lower promoter activity compared to the G allele in certain cellular contexts, though the clinical significance of this difference remains limited and subject to ongoing study.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Intermediate promoter activity
Carrying one copy of each allele results in an intermediate genetic profile for the MMP13 promoter region. Studies on this variant have produced mixed results regarding its influence on disease risk, and it is not currently used to predict specific health outcomes.
This heterozygous genotype is frequently observed across diverse populations.
Enhanced promoter activity
This genotype is associated with higher transcriptional activity of the MMP13 gene compared to the A/A genotype. While some research has explored its potential role in cancer risk or other conditions, the evidence is inconsistent and does not support using this genotype for clinical risk assessment.
This genotype is present in a significant portion of the population, with the G allele being relatively common globally.
Genomic Location and Molecular Mechanism
The single-nucleotide polymorphism rs2252070 is positioned within chromosome 11 in the promoter regulatory zone of the human matrix metallopeptidase 13 (MMP13) locus, located near other clustered matrix metalloproteinase genes. In biochemical literature, it is widely designated as the -77A>G promoter variant. Functional molecular assays, including electrophoretic mobility shift assays and reporter gene experiments, have demonstrated that the G-to-A transition directly alters transcriptional efficiency. Specifically, the presence of the G allele maintains a canonical Sp1 transcription factor binding site, which typically facilitates standard transcription. In contrast, the alternate A allele disrupts or diminishes this Sp1 recognition sequence, leading to significantly lower basal promoter activity and reduced mRNA expression in cell line models. Because promoter variants modulate gene transcription rather than altering the protein's downstream amino acid sequence, rs2252070 primarily exerts quantitative effects on enzyme availability.
Biological Role of Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) represent a multigene family of zinc-dependent endopeptidases central to extracellular matrix (ECM) breakdown and physiological tissue remodeling. Enzymes in this cluster, including collagenases like MMP-13 and related gelatinases like MMP-9, cleave structural components such as interstitial collagens, basement membrane elements, and proteoglycans. Under healthy conditions, matrix metalloproteinases orchestrate controlled processes such as embryonic development, wound repair, bone remodeling, and leukocyte extravasation. However, excessive or dysregulated enzymatic activity compromises tissue integrity and drives chronic inflammatory damage, vascular breakdown, and the remodeling of mucosal or dermal microenvironments. Because these enzymes also regulate how tissues adapt to persistent environmental stimuli—such as chronic ultraviolet radiation exposure or inflammatory cytokines—polymorphisms that alter baseline promoter efficiency provide insight into how individual cellular environments handle remodeling pressure.
Summary of Clinical and Observational Research
Epidemiological studies examining rs2252070 have primarily assessed its relationship with malignant and inflammatory pathologies across diverse populations. Multiple candidate-gene case-control evaluations, particularly in East Asian cohorts, have reported that carriers of the lower-expression A allele exhibit reduced susceptibility to certain solid tumors, notably esophageal squamous cell carcinoma (ESCC), likely due to attenuated extracellular matrix degradation by tumor-infiltrating cells. Conversely, meta-analyses encompassing thousands of oncology cases across wider global datasets frequently report neutral or contradictory associations when aggregating across diverse tumor types. Similarly, studies investigating rs2252070 in the context of chronic degenerative diseases—including periodontitis, ocular pterygium, and photoaging—show heterogeneous outcomes. Because these findings stem largely from candidate-gene designs rather than large, replicated genome-wide association studies (GWAS), clinical validity remains limited and unconfirmed for clinical prediction.
Interpreting Results: What You Can and Cannot Do
Identifying your rs2252070 genotype provides educational context regarding normal genetic variation in matrix remodeling machinery, but it does not serve as a diagnostic test. Because complex conditions like chronic inflammation, tissue degeneration, and epithelial carcinomas are driven predominantly by environmental exposures—such as tobacco smoke, alcohol, solar ultraviolet radiation, and systemic health—a single regulatory SNP exerts only a negligible relative effect. Genetic testing for this variant cannot determine whether an individual will develop tissue pathology or malignant changes. Readers should never make medical lifestyle changes, initiate supplements, or alter physician-prescribed therapies based solely on an rs2252070 result. Instead, maintaining evidence-based preventive health practices, such as routine cancer screenings, dental checkups, and broad-spectrum sun protection, remains the standard approach regardless of individual genotype.
How common is this variant?
The minor allele frequency for rs2252070 varies substantially by ancestral background, displaying an alternate allele frequency of approximately 0.15 to 0.20 in European populations according to gnomAD datasets, while reaching significantly higher frequencies across East Asian and South Asian cohorts.
Frequently asked questions
What does having the rs2252070 variant mean for my health?
Carrying an alternate allele at rs2252070 means you have a common genetic sequence variation that slightly alters the efficiency of an extracellular matrix enzyme promoter. It is not a genetic disorder and does not cause medical illness on its own. It reflects common human variation studied for subtle differences in tissue remodeling.
Does rs2252070 diagnose cancer or inflammatory diseases?
No. Complex diseases such as carcinomas and chronic inflammatory conditions arise from combinations of environmental exposures, aging, and hundreds of interactive genetic factors. Clinical professional guidelines do not use rs2252070 as a predictive or diagnostic biomarker.
How does rs2252070 affect matrix metalloproteinase proteins?
The rs2252070 polymorphism sits in a non-coding promoter region and does not change the physical structure of the enzyme itself. Instead, in vitro assays show that it modulates how tightly the regulatory protein Sp1 binds to DNA, which subtly changes the rate at which the gene produces messenger RNA.
Should I modify any medical treatment based on my rs2252070 genotype?
No, you should never stop, start, or change any medical therapy or dosage based on this variant. If you have questions about personal disease risk or therapeutic regimens, consult a licensed healthcare professional or genetic counselor.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2252070?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MMP9
Functional promoter variant (-1562C>T) in MMP9 affecting transcriptional activity and extracellular matrix remodeling.
Missense variant in MMP-9 (R279Q) altering gelatinase activity, impacting matrix degradation and structural dermal photo-aging.
Functional coding variant (R279Q) altering matrix metalloproteinase-9 activity, influencing collagen degradation and solar elastosis upon UV photo-exposure.
This SNP is associated with matrix metalloproteinase activity and cardiovascular disease risk.